The FDA broadened dupilumab's (Dupixent) approval as an add-on maintenance treatment for chronic rhinosinusitis with nasal ...

Dupilumab significantly reduced severe asthma exacerbations and SCS prescriptions vs omalizumab in patients using add-on maintenance therapy.

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

The FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.

Treatment with dupilumab led to significant improvements in remission in patients with bullous pemphigoid, an autoimmune blistering skin disease.

In a recent study investigators established that extended dupilumab therapy-up to three years-is highly effective in the ...

Study C of the phase 3 LIBERTY-CUPID trial evaluated dupilumab as add-on therapy to standard of care antihistamines in biologic-naïve patients with CSU who remained symptomatic despite antihistamine ...

Speakers at the European Respiratory Society Congress 2024 provided updates to the 2 trials focusing on depemokimab for ...

Researchers have been able to identify whether patients with atopic dermatitis who receive dupilumab treatment will respond ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a ...

Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion ...